Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab in Advanced High Grade Salivary Gland Carcinoma
NCT00126607Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jul 2005
- Primary completion
- May 2007
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab in salivary gland carcinoma (SGC), sponsored by National Cancer Institute. Started Jul 2005; status: terminated.
02
Drugs
03
Conditions
salivary gland carcinoma (SGC)
Beyond the preview
Go deeper on NCT00126607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00126607.